Alnylam Pharmaceuticals, Inc. $ALNY Position Lowered by Motley Fool Asset Management LLC

Key Points

• Motley Fool Asset Management cut its Alnylam position by 71.6% in the third quarter, selling 6,567 shares and retaining 2,603 shares valued at approximately $642,000. Institutional investors collectively own 92.97% of the company.
• Alnylam reported third-quarter revenue of about $1.46 billion, up 16.7% year over year and above expectations, while adjusted earnings beat estimates. However, the $16.26 EPS result was significantly boosted by a roughly $1.9 billion tax benefit.
• ALNY shares opened at $174, near their 52-week low, amid slowing U.S. sales growth for Amvuttra and Onpattro and recent analyst downgrades or price-target cuts. Analysts nonetheless maintain a “Moderate Buy” consensus with an average target of $355.10.

Motley Fool Asset Management LLC lessened its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 71.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,603 shares of the biopharmaceutical company's stock after selling 6,567 shares during the period. Motley Fool Asset Management LLC's holdings in Alnylam Pharmaceuticals were worth $642,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Wellington Management Group LLP lifted its stake in Alnylam Pharmaceuticals by 9.0% during the second quarter. Wellington Management Group LLP now owns 2,110,407 shares of the biopharmaceutical company's stock worth $635,296,000 after purchasing an additional 174,482 shares during the last quarter. Legal & General Group Plc bought a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at $278,321,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Alnylam Pharmaceuticals by 7.4% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 727,848 shares of the biopharmaceutical company's stock valued at $219,104,000 after purchasing an additional 50,329 shares during the last quarter. Bank of New York Mellon Corp bought a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at $148,128,000. Finally, Swiss National Bank raised its holdings in shares of Alnylam Pharmaceuticals by 7.9% during the 1st quarter. Swiss National Bank now owns 387,720 shares of the biopharmaceutical company's stock worth $128,285,000 after buying an additional 28,520 shares in the last quarter. Institutional investors own 92.97% of the company's stock.

More Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Alnylam reported third-quarter revenue of approximately $1.46 billion, up about 17% year over year and above expectations. Adjusted earnings also exceeded consensus, while the company maintained its fiscal 2026 outlook for product sales. Alnylam Reports 17% Q3 Revenue Growth
• Positive Sentiment: Management expects 2026 TTR franchise sales of roughly $4.2 billion to $4.5 billion, supported by continued demand for Amvuttra. The company also cited positive conviction in nucresiran and continued progress across its RNAi pipeline. Alnylam TTR Sales and TRITON-CM Update
• Neutral Sentiment: The $16.26 reported EPS beat was unusually large because of an approximately $1.9 billion tax benefit, making the headline result less indicative of recurring operating performance. Alnylam Q3 Tax Windfall
• Negative Sentiment: U.S. sales growth for Amvuttra and Onpattro reportedly slowed, raising concerns about the pace of the company’s core TTR franchise despite the maintained outlook. Alnylam Sales Growth Slows
• Negative Sentiment: Alnylam expanded the TRITON-CM heart-disease study for nucresiran to about 2,250 patients while retaining an expected launch around 2030. The larger trial may strengthen evidence, but it increases development demands and reinforces the long wait before a potential revenue contribution. Alnylam Nucresiran Trial Expansion
• Negative Sentiment: Stifel downgraded ALNY to Hold with a $225 price target, while Needham cut its target to $243 from $357, citing a less favorable risk-reward profile. Analysts also flagged potential policy and pricing risks. Stifel Downgrades Alnylam

Analyst Ratings Changes

ALNY has been the subject of several recent analyst reports. Weiss Ratings upgraded Alnylam Pharmaceuticals from a "hold (c-)" rating to a "hold (c)" rating in a research report on Friday, July 31st. Jefferies Financial Group lifted their target price on Alnylam Pharmaceuticals from $230.00 to $260.00 and gave the company a "hold" rating in a research report on Tuesday, September 8th. JPMorgan Chase & Co. decreased their target price on Alnylam Pharmaceuticals from $375.00 to $369.00 and set an "overweight" rating on the stock in a research report on Wednesday, September 30th. Morgan Stanley lowered their target price on Alnylam Pharmaceuticals from $400.00 to $300.00 and set an "equal weight" rating for the company in a research note on Friday, July 31st. Finally, Cantor Fitzgerald reissued a "neutral" rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, September 30th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $355.10.

Insider Buying and Selling

In other news, EVP Bryan Supran sold 1,758 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $226.88, for a total transaction of $398,855.04. Following the sale, the executive vice president directly owned 12,807 shares of the company's stock, valued at approximately $2,905,652.16. This trade represents a 12.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 0.86% of the company's stock.

Alnylam Pharmaceuticals Stock Down 25.1%

Shares of NASDAQ:ALNY opened at $174.00 on Friday. The company has a fifty day moving average of $237.78 and a 200-day moving average of $287.22. The company has a market capitalization of $23.28 billion, a PE ratio of 32.34 and a beta of 0.28. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05. Alnylam Pharmaceuticals, Inc. has a 52-week low of $172.31 and a 52-week high of $479.79.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 EPS for the quarter, beating analysts' consensus estimates of $1.66 by $14.60. The company had revenue of $1.46 billion during the quarter, compared to analysts' expectations of $1.43 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%. Alnylam Pharmaceuticals's revenue was up 16.7% compared to the same quarter last year. During the same period in the prior year, the company earned $2.90 EPS. On average, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.43 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company's therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam's marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.